Correction: Morishita et al. MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review. 2021, , 514.
1/5 보강
Following publication [...].
APA
Morishita A, Oura K, et al. (2026). Correction: Morishita et al. MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review. 2021, , 514.. Cancers, 18(2). https://doi.org/10.3390/cancers18020232
MLA
Morishita A, et al.. "Correction: Morishita et al. MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review. 2021, , 514.." Cancers, vol. 18, no. 2, 2026.
PMID
41595271 ↗
Abstract 한글 요약
Following publication [...].
같은 제1저자의 인용 많은 논문 (2)
📖 전문 본문 읽기 PMC JATS · ~15 KB · 영문
Additional Citations with Updated Citation Numbers
Additional Citations with Updated Citation Numbers
79.Jinato, T.; Chuaypen, N.; Poomipak, W.; Praianantathavorn, K.; Makkoch, J.; Kiatbumrung, R.; Jampoka, K.; Tangkijvanich, P.; Payungporn, S. Original Research: Analysis of hepatic microRNA alterations in response to hepatitis B virus infection and pegylated interferon alpha-2a treatment. Exp. Biol. Med.
2016, 241, 1803–1810.
80.Zhao, X.; Sun, L.; Mu, T.; Yi, J.; Ma, C.; Xie, H.; Liu, M.; Tang, H. An HBV-encoded miRNA activates innate immunity to restrict HBV replication. J. Mol. Cell Biol.
2020, 12, 263–276.
83.Wang, J.; Liu, X.; Wu, H.; Ni, P.; Gu, Z.; Qiao, Y.; Chen, N.; Sun, F.; Fan, Q. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res.
2010, 38, 5366–5383.
100.Bhanja Chowdhury, J.; Shrivastava, S.; Steele, R.; Di Bisceglie, A.M.; Ray, R.; Ray, R. B. Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A. J. Virol.
2012, 86, 10221–10225.
114.Khanizadeh, S.; Ravanshad, M.; Hosseini, S.Y.; Davoodian, P.; Zadeh, A.N.; Sabahi, F.; Sarvari, J.; Khanlari, Z.; Hasani-Azad, M. The possible role of NS3 protease activity of hepatitis C virus on fibrogenesis and miR-122 expression in hepatic stellate cells. Acta Virol.
2016, 60, 242–248.
281.Niu, X.; Sun, H.; Qiu, F.; Liu, J.; Yang, T.; Han, W. miR-10b-5p Suppresses the Proliferation and Invasion of Primary Hepatic Carcinoma Cells by Downregulating EphA2. Biomed. Res. Int.
2021, 2021, 1382061.
282.Dou, C.; Liu, Z.; Xu, M.; Jia, Y.; Wang, Y.; Li, Q.; Yang, W.; Zheng, X.; Tu, K.; Liu, Q., miR-187-3p inhibits the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting S100A4. Cancer Lett.
2016, 381, 380–390.
283.Zhou, S.J.; Liu, F.Y.; Zhang, A.H.; Liang, H.F.; Wang, Y.; Ma, R.; Jiang, Y.H.; Sun, N.F. MicroRNA-199b-5p attenuates TGF-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma. Br. J. Cancer
2017, 117, 233–244.
284.Yang, Q.; Zhang, L.; Zhong, Y.; Lai, L.; Li, X. miR-206 inhibits cell proliferation, invasion, and migration by down-regulating PTP1B in hepatocellular carcinoma. Biosci. Rep.
2019, 39, BSR20181823.
285.Zhang, Y.; Takahashi, S.; Tasaka, A.; Yoshima, T.; Ochi, H.; Chayama, K. Involve
ment of microRNA-224 in cell proliferation, migration, invasion, and anti-apoptosis in hepatocellular carcinoma. J. Gastroenterol. Hepatol.
2013, 28, 565–575.
286.Huo, W.; Du, M.; Pan, X.; Zhu, X.; Gao, Y.; Li, Z. miR-203a-3p.1 targets IL-24 to modulate hepatocellular carcinoma cell growth and metastasis. FEBS Open. Bio.
2017, 7, 1085–1091.
313.Azar, F.; Courtet, K.; Dekky, B.; Bonnier, D.; Dameron, O.; Colige, A.; Legagneux, V.; Theret, N. Integration of miRNA-regulatory networks in hepatic stellate cells identifies TIMP3 as a key factor in chronic liver disease. Liver Int.
2020, 40, 2021–2033.
327.Zhang, P.; Yin, J.; Yuan, L.; Wang, Q.; Du, X.; Dong, R.; Wang, C.; Bai, Q.; Ji, L.; Zhang, G.; et al. MicroRNA-139 suppresses hepatocellular carcinoma cell proliferation and migration by directly targeting Topoisomerase I. Oncol. Lett.
2019, 17, 1903–1913.
79.Jinato, T.; Chuaypen, N.; Poomipak, W.; Praianantathavorn, K.; Makkoch, J.; Kiatbumrung, R.; Jampoka, K.; Tangkijvanich, P.; Payungporn, S. Original Research: Analysis of hepatic microRNA alterations in response to hepatitis B virus infection and pegylated interferon alpha-2a treatment. Exp. Biol. Med.
2016, 241, 1803–1810.
80.Zhao, X.; Sun, L.; Mu, T.; Yi, J.; Ma, C.; Xie, H.; Liu, M.; Tang, H. An HBV-encoded miRNA activates innate immunity to restrict HBV replication. J. Mol. Cell Biol.
2020, 12, 263–276.
83.Wang, J.; Liu, X.; Wu, H.; Ni, P.; Gu, Z.; Qiao, Y.; Chen, N.; Sun, F.; Fan, Q. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res.
2010, 38, 5366–5383.
100.Bhanja Chowdhury, J.; Shrivastava, S.; Steele, R.; Di Bisceglie, A.M.; Ray, R.; Ray, R. B. Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A. J. Virol.
2012, 86, 10221–10225.
114.Khanizadeh, S.; Ravanshad, M.; Hosseini, S.Y.; Davoodian, P.; Zadeh, A.N.; Sabahi, F.; Sarvari, J.; Khanlari, Z.; Hasani-Azad, M. The possible role of NS3 protease activity of hepatitis C virus on fibrogenesis and miR-122 expression in hepatic stellate cells. Acta Virol.
2016, 60, 242–248.
281.Niu, X.; Sun, H.; Qiu, F.; Liu, J.; Yang, T.; Han, W. miR-10b-5p Suppresses the Proliferation and Invasion of Primary Hepatic Carcinoma Cells by Downregulating EphA2. Biomed. Res. Int.
2021, 2021, 1382061.
282.Dou, C.; Liu, Z.; Xu, M.; Jia, Y.; Wang, Y.; Li, Q.; Yang, W.; Zheng, X.; Tu, K.; Liu, Q., miR-187-3p inhibits the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting S100A4. Cancer Lett.
2016, 381, 380–390.
283.Zhou, S.J.; Liu, F.Y.; Zhang, A.H.; Liang, H.F.; Wang, Y.; Ma, R.; Jiang, Y.H.; Sun, N.F. MicroRNA-199b-5p attenuates TGF-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma. Br. J. Cancer
2017, 117, 233–244.
284.Yang, Q.; Zhang, L.; Zhong, Y.; Lai, L.; Li, X. miR-206 inhibits cell proliferation, invasion, and migration by down-regulating PTP1B in hepatocellular carcinoma. Biosci. Rep.
2019, 39, BSR20181823.
285.Zhang, Y.; Takahashi, S.; Tasaka, A.; Yoshima, T.; Ochi, H.; Chayama, K. Involve
ment of microRNA-224 in cell proliferation, migration, invasion, and anti-apoptosis in hepatocellular carcinoma. J. Gastroenterol. Hepatol.
2013, 28, 565–575.
286.Huo, W.; Du, M.; Pan, X.; Zhu, X.; Gao, Y.; Li, Z. miR-203a-3p.1 targets IL-24 to modulate hepatocellular carcinoma cell growth and metastasis. FEBS Open. Bio.
2017, 7, 1085–1091.
313.Azar, F.; Courtet, K.; Dekky, B.; Bonnier, D.; Dameron, O.; Colige, A.; Legagneux, V.; Theret, N. Integration of miRNA-regulatory networks in hepatic stellate cells identifies TIMP3 as a key factor in chronic liver disease. Liver Int.
2020, 40, 2021–2033.
327.Zhang, P.; Yin, J.; Yuan, L.; Wang, Q.; Du, X.; Dong, R.; Wang, C.; Bai, Q.; Ji, L.; Zhang, G.; et al. MicroRNA-139 suppresses hepatocellular carcinoma cell proliferation and migration by directly targeting Topoisomerase I. Oncol. Lett.
2019, 17, 1903–1913.
Removed Citations
Removed Citations
80.Fisicaro, P.; Valdatta, C.; Boni, C.; Massari, M.; Mori, C.; Zerbini, A.; Orlandini, A.; Sacchelli, L.; Missale, G.; Ferrari, C. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut
2009, 58, 974–982. https://doi.org/10.1136/gut.2008.163600.
81.Mizuguchi, Y.; Takizawa, T.; Yoshida, H.; Uchida, E. Dysregulated miRNA in progression of hepatocellular carcinoma: A systematic review. Hepatol. Res. 2016, 46, 391–406. https://doi.org/10.1111/hepr.12606.
82.Bertoletti, A.; Kennedy, P.T.F. The immune tolerant phase of chronic HBV infection: New perspectives on an old concept. Cell. Mol. Immunol. 2014, 12, 258–263. https://doi.org/10.1038/cmi.2014.79.
100.Chowdhury, J.B.; Shrivastava, S.; Steele, R.; Di Bisceglie, A.M.; Ray, R.; Ray, R.B. Hepatitis C Virus Infection Modulates Expression of Interferon Stimulatory Gene IFITM1 by Upregulating miR-130A. J. Virol. 2012, 86, 10221–10225. https://doi.org/10.1128/jvi.00882-12.
109.Wan, Y.; McDaniel, K.; Wu, N.; Ramos-Lorenzo, S.; Glaser, T.; Venter, J.; Francis, H.; Kennedy, L.; Sato, K.; Zhou, T.; et al. Regulation of Cellular Senescence by miR-34a in Alcoholic Liver Injury. Am. J. Pathol. 2017, 187, 2788–2798. https://doi.org/10.1016/j.ajpath.2017.08.027.
115.Wu, F.-L.; Jin, W.-B.; Li, J.-H.; Guo, A.-G. Targets for human encoded microRNAs in HBV genes. Virus Genes 2011, 42, 157–161. https://doi.org/10.1007/s11262-010-0555-7.
152.Tian, Q.; Xiao, Y.; Wu, Y.; Liu, Y.; Song, Z.; Gao, W.; Zhang, J.; Yang, J.; Zhang, Y.; Guo, T.; et al. MicroRNA-33b suppresses the proliferation and metastasis of hepatocellular carcinoma cells through the inhibition of Sal-like protein 4 expression. Int. J. Mol. Med. 2016, 38, 1587–1595. https://doi.org/10.3892/ijmm.2016.2754. Retracted in Int. J. Mol. Med. 2021, 48, 170.
172.Cui, S.; Sun, Y.; Liu, Y.; Liu, C.; Wang, J.; Hao, G.; Sun, Q. MicroRNA-137 has a suppressive role in liver cancer via targeting EZH2. Mol. Med. Rep.
2017, 16, 9494–9502. https://doi.org/10.3892/mmr.2017.7828. Retracted in Mol. Med. Rep.
2022, 25, 145.
208.Wang, L.; Yao, J.; Sun, H.; Sun, R.; Chang, S.; Yang, Y.; Song, T.; Huang, C. miR-302b suppresses cell invasion and metastasis by directly targeting AKT2 in human hepatocellular carcinoma cells. Tumor Biol.
2016, 37, 847–855.
221.Ye, Y.; Zhuang, J.; Wang, G.; He, S.; Zhang, S.; Wang, G.; Ni, J.; Wang, J.; Xia, W. MicroRNA 495 suppresses cell proliferation and invasion of hepatocellular carcinoma by directly targeting insulin like growth factor receptor 1. Exp. Ther. Med.
2018, 15, 1150–1158. https://doi.org/10.3892/etm.2017.5467. Retracted in Exp Ther Med. 2022, 24, 505.
232.Yang, C.; Xu, Y.; Cheng, F.; Hu, Y.; Yang, S.; Rao, J.; Wang, X. miR-1301 inhibits hepatocellular carcinoma cell migration, invasion, and angiogenesis by decreasing Wnt/β-catenin signaling through targeting BCL9. Cell Death Dis. 2017, 8, e2999. https://doi.org/10.1038/cddis.2017.356. Retracted in Cell Death Dis. 2023, 14, 225.
283.Liu, Z.; Wang, Y.; Dou, C.; Sun, L.; Li, Q.; Wang, L.; Xu, Q.; Yang, W.; Liu, Q.; Tu, K. MicroRNA-1468 promotes tumor progression by activating PPAR-γ-mediated AKT signaling in human hepatocellular carcinoma. J. Exp. Clin. Cancer Res.
2018, 37, 49. https://doi.org/10.1186/s13046-018-0717-3. Retracted in J. Exp. Clin. Cancer Res.
2022, 41, 272.
295.Yoon, J.S.; Kim, G.; Lee, Y.R.; Park, S.Y.; Tak, W.Y.; Kweon, Y.O.; Park, J.G.; Lee, H.W.; Han, Y.S.; Ha, H.T.; et al. Clinical significance of microRNA-21 expression in disease progression of patients with hepatocellular carcinoma. Biomark. Med. 2018, 12, 1105–1114. https://doi.org/10.2217/bmm-2018-0096.
309.Garofalo, M.; Di Leva, G.; Romano, G.; Nuovo, G.; Suh, S.-S.; Ngankeu, A.; Taccioli, C.; Pichiorri, F.; Alder, H.; Secchiero, P.; et al. miR-221&222 Regulate TRAIL Resistance and Enhance Tumorigenicity through PTEN and TIMP3 Downregulation. Cancer Cell 2009, 16, 498–509. https://doi.org/10.1016/j.ccr.2009.10.014. Retracted in Cancer Cell
2022, 40, 1440.
315.Yuan, B.; Dong, R.; Shi, D.; Zhou, Y.; Zhao, Y.; Miao, M.; Jiao, B. Down-regulation of miR-23b may contribute to activation of the TGF-β1/Smad3 signalling pathway during the termination stage of liver regeneration. FEBS Lett. 2011, 585, 927–934. https://doi.org/10.1016/j.febslet.2011.02.031.
340.Guo, Y.; Xiong, Y.; Sheng, Q.; Zhao, S.; Wattacheril, J.; Flynn, C.R. A micro-RNA expression signature for human NAFLD progression. J. Gastroenterol. 2016, 51, 1022–1030.
345.Li, L.-M.; Hu, Z.-B.; Zhou, Z.-X.; Chen, X.; Liu, F.-Y.; Zhang, J.-F.; Shen, H.-B.; Zhang, C.-Y.; Zen, K. Serum microRNA Profiles Serve as Novel Biomarkers for HBV Infection and Diagnosis of HBV-Positive Hepatocarcinoma. Cancer Res. 2010, 70, 9798–9807. https://doi.org/10.1158/0008-5472.can-10-1001.
350.Fu, X.; Liu, M.; Qu, S.; Ma, J.; Zhang, Y.; Shi, T.; Wen, H.; Yang, Y.; Wang, S.; Wang, J.; et al. Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway. J. Exp. Clin. Cancer Res. 2018, 37, 52. https://doi.org/10.1186/s13046-018-0677-7. Retracted in J. Exp. Clin. Cancer Res. 2023, 42, 174.
80.Fisicaro, P.; Valdatta, C.; Boni, C.; Massari, M.; Mori, C.; Zerbini, A.; Orlandini, A.; Sacchelli, L.; Missale, G.; Ferrari, C. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut
2009, 58, 974–982. https://doi.org/10.1136/gut.2008.163600.
81.Mizuguchi, Y.; Takizawa, T.; Yoshida, H.; Uchida, E. Dysregulated miRNA in progression of hepatocellular carcinoma: A systematic review. Hepatol. Res. 2016, 46, 391–406. https://doi.org/10.1111/hepr.12606.
82.Bertoletti, A.; Kennedy, P.T.F. The immune tolerant phase of chronic HBV infection: New perspectives on an old concept. Cell. Mol. Immunol. 2014, 12, 258–263. https://doi.org/10.1038/cmi.2014.79.
100.Chowdhury, J.B.; Shrivastava, S.; Steele, R.; Di Bisceglie, A.M.; Ray, R.; Ray, R.B. Hepatitis C Virus Infection Modulates Expression of Interferon Stimulatory Gene IFITM1 by Upregulating miR-130A. J. Virol. 2012, 86, 10221–10225. https://doi.org/10.1128/jvi.00882-12.
109.Wan, Y.; McDaniel, K.; Wu, N.; Ramos-Lorenzo, S.; Glaser, T.; Venter, J.; Francis, H.; Kennedy, L.; Sato, K.; Zhou, T.; et al. Regulation of Cellular Senescence by miR-34a in Alcoholic Liver Injury. Am. J. Pathol. 2017, 187, 2788–2798. https://doi.org/10.1016/j.ajpath.2017.08.027.
115.Wu, F.-L.; Jin, W.-B.; Li, J.-H.; Guo, A.-G. Targets for human encoded microRNAs in HBV genes. Virus Genes 2011, 42, 157–161. https://doi.org/10.1007/s11262-010-0555-7.
152.Tian, Q.; Xiao, Y.; Wu, Y.; Liu, Y.; Song, Z.; Gao, W.; Zhang, J.; Yang, J.; Zhang, Y.; Guo, T.; et al. MicroRNA-33b suppresses the proliferation and metastasis of hepatocellular carcinoma cells through the inhibition of Sal-like protein 4 expression. Int. J. Mol. Med. 2016, 38, 1587–1595. https://doi.org/10.3892/ijmm.2016.2754. Retracted in Int. J. Mol. Med. 2021, 48, 170.
172.Cui, S.; Sun, Y.; Liu, Y.; Liu, C.; Wang, J.; Hao, G.; Sun, Q. MicroRNA-137 has a suppressive role in liver cancer via targeting EZH2. Mol. Med. Rep.
2017, 16, 9494–9502. https://doi.org/10.3892/mmr.2017.7828. Retracted in Mol. Med. Rep.
2022, 25, 145.
208.Wang, L.; Yao, J.; Sun, H.; Sun, R.; Chang, S.; Yang, Y.; Song, T.; Huang, C. miR-302b suppresses cell invasion and metastasis by directly targeting AKT2 in human hepatocellular carcinoma cells. Tumor Biol.
2016, 37, 847–855.
221.Ye, Y.; Zhuang, J.; Wang, G.; He, S.; Zhang, S.; Wang, G.; Ni, J.; Wang, J.; Xia, W. MicroRNA 495 suppresses cell proliferation and invasion of hepatocellular carcinoma by directly targeting insulin like growth factor receptor 1. Exp. Ther. Med.
2018, 15, 1150–1158. https://doi.org/10.3892/etm.2017.5467. Retracted in Exp Ther Med. 2022, 24, 505.
232.Yang, C.; Xu, Y.; Cheng, F.; Hu, Y.; Yang, S.; Rao, J.; Wang, X. miR-1301 inhibits hepatocellular carcinoma cell migration, invasion, and angiogenesis by decreasing Wnt/β-catenin signaling through targeting BCL9. Cell Death Dis. 2017, 8, e2999. https://doi.org/10.1038/cddis.2017.356. Retracted in Cell Death Dis. 2023, 14, 225.
283.Liu, Z.; Wang, Y.; Dou, C.; Sun, L.; Li, Q.; Wang, L.; Xu, Q.; Yang, W.; Liu, Q.; Tu, K. MicroRNA-1468 promotes tumor progression by activating PPAR-γ-mediated AKT signaling in human hepatocellular carcinoma. J. Exp. Clin. Cancer Res.
2018, 37, 49. https://doi.org/10.1186/s13046-018-0717-3. Retracted in J. Exp. Clin. Cancer Res.
2022, 41, 272.
295.Yoon, J.S.; Kim, G.; Lee, Y.R.; Park, S.Y.; Tak, W.Y.; Kweon, Y.O.; Park, J.G.; Lee, H.W.; Han, Y.S.; Ha, H.T.; et al. Clinical significance of microRNA-21 expression in disease progression of patients with hepatocellular carcinoma. Biomark. Med. 2018, 12, 1105–1114. https://doi.org/10.2217/bmm-2018-0096.
309.Garofalo, M.; Di Leva, G.; Romano, G.; Nuovo, G.; Suh, S.-S.; Ngankeu, A.; Taccioli, C.; Pichiorri, F.; Alder, H.; Secchiero, P.; et al. miR-221&222 Regulate TRAIL Resistance and Enhance Tumorigenicity through PTEN and TIMP3 Downregulation. Cancer Cell 2009, 16, 498–509. https://doi.org/10.1016/j.ccr.2009.10.014. Retracted in Cancer Cell
2022, 40, 1440.
315.Yuan, B.; Dong, R.; Shi, D.; Zhou, Y.; Zhao, Y.; Miao, M.; Jiao, B. Down-regulation of miR-23b may contribute to activation of the TGF-β1/Smad3 signalling pathway during the termination stage of liver regeneration. FEBS Lett. 2011, 585, 927–934. https://doi.org/10.1016/j.febslet.2011.02.031.
340.Guo, Y.; Xiong, Y.; Sheng, Q.; Zhao, S.; Wattacheril, J.; Flynn, C.R. A micro-RNA expression signature for human NAFLD progression. J. Gastroenterol. 2016, 51, 1022–1030.
345.Li, L.-M.; Hu, Z.-B.; Zhou, Z.-X.; Chen, X.; Liu, F.-Y.; Zhang, J.-F.; Shen, H.-B.; Zhang, C.-Y.; Zen, K. Serum microRNA Profiles Serve as Novel Biomarkers for HBV Infection and Diagnosis of HBV-Positive Hepatocarcinoma. Cancer Res. 2010, 70, 9798–9807. https://doi.org/10.1158/0008-5472.can-10-1001.
350.Fu, X.; Liu, M.; Qu, S.; Ma, J.; Zhang, Y.; Shi, T.; Wen, H.; Yang, Y.; Wang, S.; Wang, J.; et al. Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway. J. Exp. Clin. Cancer Res. 2018, 37, 52. https://doi.org/10.1186/s13046-018-0677-7. Retracted in J. Exp. Clin. Cancer Res. 2023, 42, 174.
출처: PubMed Central (JATS). 라이선스는 원 publisher 정책을 따릅니다 — 인용 시 원문을 표기해 주세요.